Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Charlotte Gesson"'
Autor:
Charlotte Gesson, Sylvain Fouliard, Marylore Chenel, François Bouzom, Sophie Peigné, Karl Brendel
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 43:13-27
The main objective was to help design a paediatric study for ivabradine, a compound already marketed in adults, focusing on: the paediatric formulation evaluation, the doses to be administered, the sampling design and the sampling technique. A second
Autor:
Cyrielle Dumont, France Mentré, Clare Gaynor, Karl Brendel, Charlotte Gesson, Marylore Chenel
Publikováno v:
Clinical Pharmacokinetics
Clinical Pharmacokinetics, Springer Verlag, 2013, 52 (1), pp.43-57. ⟨10.1007/s40262-012-0022-9⟩
Clinical Pharmacokinetics, Springer Verlag, 2013, 52 (1), pp.43-57. ⟨10.1007/s40262-012-0022-9⟩
International audience; BACKGROUND: Since 2007, it is mandatory for the pharmaceutical companies to submit a Paediatric Investigation Plan to the Paediatric Committee at the European Medicines Agency for any drug in development in adults, and it ofte
Autor:
Ole J. Bjerrum, J Alder, Charlotte Gesson, R. Colin Garner, J. Brian Houston, B. Oosterhuis, Malcolm Rowland, Roeline Jochemsen, Richard John Weaver, Yoko Shishikura, Graham Lappin, Grzegorz Grynkiewicz
Publikováno v:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 43(3)
A clinical study was conducted to assess the ability of a microdose (100 μg) to predict the human pharmacokinetics (PK) following a therapeutic dose of clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen) and phenobarbital, both wit
Autor:
Ole J. Bjerrum, Brian Houston, Charlotte Gesson, R. Colin Garner, Malcolm Rowland, Roeline Jochemsen, Yoko Shishikura, Graham Lappin, Richard John Weaver, B. Oosterhuis
Publikováno v:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 40(2)
A human pharmacokinetic study was performed to assess the ability of a microdose to predict the pharmacokinetics of a therapeutic dose of fexofenadine and to determine its absolute oral bioavailability. Fexofenadine was chosen to represent an unmetab